Gabriele Fragasso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8149592/publications.pdf

Version: 2024-02-01

78	2,996	218677	161849
papers	citations	26 h-index	54 g-index

82	82	82	3329
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure. Journal of the American College of Cardiology, 2006, 48, 992-998.	2.8	225
2	Metabolic Therapy for Patients with Diabetes Mellitus and Coronary Artery Disease. American Journal of Cardiology, 2006, 98, 14-18.	1.6	225
3	Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. European Heart Journal, 2006, 27, 942-948.	2.2	210
4	Association of Insulin Resistance, Hyperleptinemia, and Impaired Nitric Oxide Release With In-Stent Restenosis in Patients Undergoing Coronary Stenting. Circulation, 2003, 108, 2074-2081.	1.6	175
5	Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia. European Journal of Endocrinology, 2004, 151, 483-489.	3.7	138
6	Comparison of stress/rest myocardial perfusion tomography, dipyridamole and dobutamine stress echocardiography for the detection of coronary disease in hypertensive patients with chest pain and positive exercise test. Journal of the American College of Cardiology, 1999, 34, 441-447.	2.8	128
7	Assessment of Stress-induced Pulmonary Interstitial Edema by Chest Ultrasound During Exercise Echocardiography and its Correlation with Left Ventricular Function. Journal of the American Society of Echocardiography, 2006, 19, 457-463.	2.8	118
8	Effect of oral l-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. American Journal of Cardiology, 2004, 93, 933-935.	1.6	114
9	Acute Intravenous l -Arginine Infusion Decreases Endothelin-1 Levels and Improves Endothelial Function in Patients With Angina Pectoris and Normal Coronary Arteriograms. Circulation, 2003, 107, 429-436.	1.6	105
10	Sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503.	7.1	100
11	Specificity and sensitivity of exercise-induced st segment elevation for detection of residual viability: Comparison with fluorodeoxyglucose and positron emission tomography. Journal of the American College of Cardiology, 1995, 25, 1032-1038.	2.8	86
12	Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. American Journal of Cardiology, 1998, 82, 898-901.	1.6	84
13	Tumor Necrosis Factor Î± As a Master Regulator of Inflammation in Erdheim-Chester Disease: Rationale for the Treatment of Patients With Infliximab. Journal of Clinical Oncology, 2012, 30, e286-e290.	1.6	79
14	Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study. International Journal of Cardiology, 2013, 163, 320-325.	1.7	77
15	Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. American Journal of Physiology - Endocrinology and Metabolism, 2006, 290, E54-E59.	3.5	67
16	Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. International Journal of Cardiology, 2016, 203, 909-915.	1.7	67
17	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2020, 22, 1984-1986.	7.1	66
18	Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries. Journal of the American College of Cardiology, 1999, 34, 1452-1460.	2.8	61

#	Article	IF	Citations
19	Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart, 2011, 97, 1495-1500.	2.9	60
20	Time course and determinants of left ventricular function recovery after primary angioplasty in patients with acute myocardial infarction. Journal of the American College of Cardiology, 2001, 38, 464-471.	2.8	52
21	Coronary slow-flow causing transient myocardial hypoperfusion in patients with cardiac syndrome X: Long-term clinical and functional prognosis. International Journal of Cardiology, 2009, 137, 137-144.	1.7	52
22	Symptom-limited exercise testing causes sustained diastolic dysfunction in patients with coronary disease and low effort tolerance. Journal of the American College of Cardiology, 1991, 17, 1251-1255.	2.8	44
23	Two-year cardiac mortality after MitraClip treatment of functional mitral regurgitation in ischemic and non-ischemic dilated cardiomyopathy. International Journal of Cardiology, 2018, 269, 33-39.	1.7	42
24	Effect of Atenolol on QT Interval and Dispersion in Patients With Syndrome X. American Journal of Cardiology, 1997, 80, 789-790.	1.6	33
25	Usefulness of holter monitoring to improve the sensitivity of exercise testing in determining the degree of myocardial revascularization after coronary artery bypass grafting for stable angina pectoris. American Journal of Cardiology, 1987, 60, 40-43.	1.6	29
26	Beneficial Electrophysiological Effects of Trimetazidine in Patients With Postischemic Chronic Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 24-30.	2.0	28
27	Feasibility and safety of transcatheter closure of atrial septal defects with deficient posterior rim. Catheterization and Cardiovascular Interventions, 2013, 81, 1180-1187.	1.7	27
28	Beneficial effects of betaâ€blockers on left ventricular function and cellular energy reserve in patients with heart failure. Fundamental and Clinical Pharmacology, 2013, 27, 455-464.	1.9	27
29	Enoximone Echocardiography for Predicting Recovery of Left Ventricular Dysfunction After Revascularization. Circulation, 2000, 101, 1255-1260.	1.6	25
30	Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease. Journal of the American College of Cardiology, 2002, 39, 413-419.	2.8	25
31	Erectile dysfunction in heart failure patients: a critical reappraisal. Andrology, 2013, 1, 177-191.	3.5	23
32	Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase. Current Clinical Pharmacology, 2007, 2, 190-196.	0.6	21
33	Differential Long-term Effects of Carvedilol on Proinflammatory and Antiinflammatory Cytokines, Asymmetric Dimethylarginine, and Left Ventricular Function in Patients With Heart Failure. Journal of Cardiovascular Pharmacology, 2008, 52, 49-54.	1.9	21
34	Antiischemic Effects of Intravenous Diazepam in Patients with Coronary Artery Disease. Journal of Cardiovascular Pharmacology, 1994, 24, 55-58.	1.9	20
35	Nitric-Oxide Mediated Effects of Transdermal Capsaicin Patches on the Ischemic Threshold in Patients with Stable Coronary Disease. Journal of Cardiovascular Pharmacology, 2004, 44, 340-347.	1.9	20
36	Validation of Remote Cardiopulmonary Examination in Patients With Heart Failure With a Videophone-Based System. Journal of Cardiac Failure, 2007, 13, 281-286.	1.7	19

#	Article	IF	Citations
37	Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease. Current Pharmaceutical Design, 2009, 15, 857-862.	1.9	19
38	Risk of cardiac and sudden death with and without revascularisation of a coronary chronic total occlusion. Heart, 2019, 105, 1096-1102.	2.9	19
39	Deranged cardiac metabolism and the pathogenesis of heart failure. Cardiac Failure Review, 2016, 2, 8.	3.0	19
40	Early detection by the Tei index of carvedilol-induced improved left ventricular function in patients with heart failure. American Journal of Cardiology, 2004, 94, 1456-1459.	1.6	18
41	Metabolic Therapy of Heart Failure. Current Pharmaceutical Design, 2008, 14, 2582-2591.	1.9	18
42	Cardiotoxicity after low-dose chloroquine antimalarial therapy. Heart and Vessels, 2009, 24, 385-387.	1.2	18
43	Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure. International Journal of Clinical Practice, 2007, 61, 603-610.	1.7	17
44	Influence of treatment delay on long-term left ventricular function in patients with acute myocardial infarction successfully treated with primary angioplasty. American Heart Journal, 2001, 141, 603-609.	2.7	15
45	Resting cardiac energy metabolism is inversely associated with heart rate in healthy young adult men. American Heart Journal, 2011, 162, 136-141.	2.7	12
46	Prognostic role of stress/rest myocardial perfusion scintigraphy in patients with cardiac syndrome x. International Journal of Cardiology, 2014, 173, 467-471.	1.7	10
47	Extracorporeal myocardial shockwave therapy; a precious blast for refractory angina patients. Cardiovascular Revascularization Medicine, 2018, 19, 263-267.	0.8	10
48	Comparison of Exercise Electrocardiography, Technetium-99m Sestamibi Single Photon Emission Computed Tomography, and Dobutamine and Dipyridamole Echocardiography for Detection of Coronary Artery Disease in Hypertensive Women. American Journal of Cardiology, 2010, 105, 1254-1260.	1.6	9
49	Pathophysiologic therapeutic targets in hypertension: a cardiological point of view. Expert Opinion on Therapeutic Targets, 2012, 16, 179-193.	3.4	9
50	Metabolic effects of cardiovascular drugs. Trends in Cardiovascular Medicine, 2019, 29, 176-187.	4.9	9
51	The anti-ischemic effect of trimetazidine in patients with postprandial myocardial ischemia is unrelated to meal composition. American Heart Journal, 2006, 151, 1238.e1-1238.e8.	2.7	8
52	Safety and efficacy of doxazosin as an 'add-on' antihypertensive therapy in mild to moderate heart failure patients. Acta Cardiologica, 2009, 64, 485-491.	0.9	8
53	Pathophysiological Mechanisms and Correlates of Therapeutic Pharmacological Interventions in Essential Arterial Hypertension. Advances in Experimental Medicine and Biology, 2016, 956, 37-59.	1.6	8
54	Elderly manifestation of non-compaction of the ventricular myocardium. Journal of Cardiovascular Medicine, 2006, 7, 714-716.	1.5	7

#	Article	IF	Citations
55	Early left atrial tissue features in patients with chronic mitral regurgitation and sinus rhythm: Alterations of not remodeled left atria. International Journal of Cardiology, 2016, 219, 433-438.	1.7	7
56	Heart Rate Reduction Is Probably Not the Main Beneficial Mechanism by Which Beta Blockade Improves Outcome in Patients With Systolic Chronic Heart Failure. American Journal of Cardiology, 2008, 102, 506-507.	1.6	6
57	Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure. Journal of Cardiovascular Medicine, 2013, 14, 49-56.	1.5	6
58	Septal Panniculitis Induced by Atenolol. Angiology, 1998, 49, 499-502.	1.8	5
59	Validation of heart and lung teleauscultation on an Internet-Based system. American Journal of Cardiology, 2003, 92, 1138-1139.	1.6	5
60	Magnetic resonance image (MRI) of an acquired aorto-pulmonary fistula, associated with cerebral and paradoxical embolism. International Journal of Cardiology, 2002, 83, 85-86.	1.7	4
61	Different Metabolic Effects of Selective and Nonselective Beta-Blockers Rather Than Mere Heart Rate Reduction May Be the Mechanisms by Which Beta-Blockade Prevents Cardiovascular Events. Journal of the American College of Cardiology, 2009, 53, 2105.	2.8	4
62	Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure. Journal of Cardiovascular Medicine, 2018, 19, 351-356.	1.5	4
63	Real-Life Indications to Sacubitril/Valsartan Treatment in Patients With Chronic Systolic Heart Failure. Journal of Cardiovascular Pharmacology, 2019, 73, 301-306.	1.9	4
64	Validation of a new score for outcome prediction in patients with heart failure with reduced ejection fraction. Minerva Cardioangiologica, 2019, 67, 191-199.	1.2	4
65	New directions in the treatment of heart failure: Targeting free fatty acid oxidation. Current Heart Failure Reports, 2007, 4, 236-242.	3.3	3
66	A high carbohydrate meal yields a lower ischemic threshold than a high fat meal in patients with stable coronary disease. International Journal of Cardiology, 2011, 147, 209-213.	1.7	3
67	Prognosis of mild/moderate chronic systolic heart failure. International Journal of Cardiology, 2010, 145, 584-586.	1.7	2
68	Age-related reduction of myocardial metabolic efficiency: Is it time to routinely measure myocardial metabolism to monitor cardiac health?. Heart, 2018, 104, 88-89.	2.9	2
69	Longâ€term clinical effects of recanalization of chronic coronary total occlusions in patients with left ventricular systolic dysfunction. Catheterization and Cardiovascular Interventions, 2020, 96, 831-838.	1.7	2
70	Editorial Commentary: Drug dosing optimization in heart failure: Need of a multidimensional approach (and skilled heart failure specialists). Trends in Cardiovascular Medicine, 2021, 31, 117-118.	4.9	2
71	Oral direct thrombin inhibition: a double-edged sword?. Heart, Lung and Vessels, 2015, 7, 191-7.	0.4	2
72	Letter by Fragasso et al Regarding Article by Tuunanen et al, â€œFree Fatty Acid Depletion Acutely Decreases Cardiac Work and Efficiency in Cardiomyopathic Heart Failureâ€. Circulation, 2007, 115, e546; author reply e547.	1.6	1

#	Article	IF	Citations
73	Improved survival in patients with chronic mild/moderate systolic heart failure followed up in a specialist clinic. Journal of Cardiovascular Medicine, 2013, 14, 57-65.	1.5	1
74	Editorial commentary: Pathophysiological effects of proton pump inhibitors in cardiac patients: Time for a critical reappraisal. Trends in Cardiovascular Medicine, 2019, 29, 361-362.	4.9	1
75	Role of Metabolic Modulation in the Management of Chronic Ischemic Heart Disease. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S3159.	0.4	0
76	Myocardial 99m-Tc tetrofosmin reverse redistribution as a possible marker of tissue at risk. Anatolian Journal of Cardiology, 2012, 13, 184-6.	0.4	0
77	Pathophysiological mechanisms should be taken into account and guide the treatment of essential arterial hypertension. Indian Heart Journal, 2017, 69, 417.	0.5	0
78	Vasostatin-1 as a potential novel circulating biomarker in patients with chronic systolic heart failure: A pilot study. Clinica Chimica Acta, 2022, 526, 49-54.	1.1	0